Survival Outcome and EMT Suppression Mediated by a Lectin Domain Interaction of Endo180 and CD147


Abstract

Epithelial cell–cell contacts maintain normal glandular tissue homeostasis, and their breakage can trigger epithelial-to-mesenchymal transition (EMT), a fundamental step in the development of metastatic cancer. Despite the ability of C-type lectin domains (CTLD) to modulate cell–cell adhesion, it is not known if they modulate epithelial adhesion in EMT and tumor progression. Here, the multi-CTLD mannose receptor, Endo180 (MRC2/uPARAP), was shown using the Kaplan–Meier analysis to be predictive of survival outcome in men with early prostate cancer. A proteomic screen of novel interaction partners with the fourth CTLD (CTLD4) in Endo180 revealed that its complex with CD147 is indispensable for the stability of three-dimensional acini formed by nontransformed prostate epithelial cells (PEC). Mechanistic study using knockdown of Endo180 or CD147, and treatment with an Endo180 mAb targeting CTLD4 (clone 39.10), or a dominant-negative GST-CTLD4 chimeric protein, induced scattering of PECs associated with internalization of Endo180 into endosomes, loss of E-cadherin (CDH1/ECAD), and unzipping of cell–cell junctions. These findings are the first to demonstrate that a CTLD acts as a suppressor and regulatory switch for EMT; thus, positing that stabilization of Endo180–CD147 complex is a viable therapeutic strategy to improve rates of prostate cancer survival.

Implications: This study identifies the interaction between CTLD4 in Endo180 and CD147 as an EMT suppressor and indicates that stabilization of this molecular complex improves prostate cancer survival rates.

Visual Overview: http://mcr.aacrjournals.org/content/early/2015/03/09/1541-7786.MCR-14-0344-T/F1.large.jpg

Mol Cancer Res; 13(3); 1–10. ©2014 AACR.

Introduction

Epithelial-to-mesenchymal transition (EMT) is a reversible transdifferentiation program involving a switch from the apical-to-basal polarization of epithelial cells, which are adherent to each other and the basement membrane, to a detached mesenchymal-like phenotype that is highly motile and invasive (1). EMT is defined according to its different biologic contexts, including normal embryonic development (type I EMT), wound healing, tissue regeneration and organ fibrosis (type II EMT), or tumor progression (type III EMT; ref. 2). EMT has also been closely linked to the early stages of tumor development, following the finding that EMT-associated metastatic dissemination precedes detectable adenocarcinoma formation in glandular tissue (3). This strongly suggests that molecular triggers of EMT in normal epithelial layers should be prioritized as targets for the development of therapeutics that can prevent metastasis and improve cancer survival rates.

C-type lectin domains (CTLD) facilitate the Ca2+-dependent interaction of cell surface receptors with carbohydrate moieties, playing critical roles in the innate immune response to pathogens, glycoprotein turnover, and modulation of cell–matrix and cell–cell interactions (4). In a biomarker study, we have previously revealed that the multi-CTLD receptor Endo180 (CD280, CLEC13E, KIAA0709, MRC2, TEM9, uPARAP) is highly expressed in cells with an EMT-like phenotype and correlated with Gleason score in prostate cancer (5). In the same study, Endo180 expression was observed in epithelial cells lining the ducts of glandular tissue affected by benign prostatic hyperplasia (BPH) or low-grade prostate cancer (5). Given that Endo180 expression and subcellular localization in constitutively recycling endosomes in mesenchymal-like tumor cells promote extracellular matrix (ECM) remodelling (6–10), disassembly of cell–cell and cell–matrix adhesions and cell motility (11, 12), and enhanced tumor growth (7), we hypothesized that these pro-EMT properties are negatively regulated in
normal prostate epithelial cells (PEC). In accordance, this study has identified a novel EMT-suppressor complex between the fourth of eight CTLDs, CTLD4, in Endo 180 and the cell adhesion modulator CD147 that is dispensable for PEC stability. We suggest that disruption of the suppressive Endo180–CD147 complex contributes to the marked decrease in survival attributed to Endo180 expression in low-to-intermediate grade (Gleason 5–7) prostate cancer. Hence, stabilization of the interaction between CTLD4 in Endo180 and CD147 is a promising therapeutic strategy that could suppress EMT and metastatic dissemination at the early stages of prostate adenocarcinoma formation.

Materials and Methods

Immunohistochemical analysis

The tissue biopsies on the NCLPC1 and NCLPC4 prostate cancer tissue microarrays (TMA) used in this study were obtained with consent and approved by the Research Ethics Committee of Newcastle University Medical School. Both TMAs were immunostained with the Endo180 mAb 39.10 (Supplementary Table S1; refs. 5, 7, & 8) and a Histostain-Plus detection kit (Invitrogen). Images were collected using a Zeiss ChromaVision ACIS II automated slide scanner, an Olympus UPlanFLN 10X objective (N.A. = 0.30), and a Sony progressive CCD (charge-coupled device) color video camera. Immunohistochemical scores were calculated as percent positive cells (0 to 100) × staining intensity (0 to 3) with a cutoff score of 30 (range, 0–300) distinguishing positive from negative tumors. This immunohistochemical scoring system is in routine use in the Departments of Medicine and Surgery and Cancer at Imperial College London (13).

Cell culture, treatment, and morphologic analysis

RWPE-1, PC3, DU145, and B16-F10 were obtained from the American Type Culture Collection, where they were verified by short tandem repeat profiling and phenotypic analysis. BPH-1 cells were obtained from Dr. Simon Hayward (Vanderbilt University Medical Center) under a material transfer agreement and verified by phenotypic analysis. Cells were frozen in liquid nitrogen, and fresh aliquots were defrosted and tested for mycoplasma every three months (VenorGen Mycoplasma Detection Kit) before their experimental use for up to ten passages. RWPE-1 cells were grown in complete keratinocyte serum-free media before their experimental use for up to ten passages. RWPE-1 cells were grown in complete RPMI 1640 medium supplemented with 2 mmol/L l-glutamine, penicillin (50 U/mL) and streptomycin (50 μg/mL), and 10% v/v (PC3, DU145, and B16-F10) or 5% v/v (BPH-1) FCS. For three-dimensional (3D) acini (RWPE-1 or BPH-1) or 3D aggregate (DU145 or PC3) cultures, cells were seeded (5 × 10^3 per well) in 8-well chamber slides (Millipore Ltd.) precoated with CultiTrex 3D Culture Matrix reduced growth factor reconstituted basement membrane (rBM) extract (#3445-005-01; Trevigen) and overlaid with growth medium + 2% v/v CultiTrex rBM. Cells were transiently transfected with expression vectors or siRNA oligonucleotides (see Supplementary Methods; refs. 8, 11, 12). In brief, 24 hours after siRNAs transfection cells were transfected either with Endo180-Flag or Flag only, expression vectors were incubated overnight at 37°C with 5% v/v CO₂. Cells were seeded (5 × 10^3 per well) onto rBM, and remaining cells were lysed for assessment of knockdown efficiency using immunoblot analysis. Knockdown was sustained for the 4-day duration of the assay. Other treatments included addition of A5/158 or 39.10 mAbs, nonspecific negative control IgG (#ab37355; Abcam), GST, GST-CTLD2, or GST-CTLD4 (see Supplementary Methods) to the culture medium with daily replacement. A blinded manual scoring approach (two independent scorers) was used to calculate the percentage of acini containing ≥4 cells for each condition relative to the control (set at 100%).

Immunoblotting and immunofluorescent staining

Immunoblotting and immunofluorescent staining of monolayers and 3D cultures were carried out with primary antibodies (Supplementary Table S1) and appropriate horseradish peroxidase–conjugated or AlexaFluor-conjugated secondary antibodies (8, 11, 12, 14). For immunoblots, relative signal intensities for each band were quantified using Image J (Version 1.42q), adjusted for loading (GAPDH or ERK-2), and normalized against untreated samples (relative levels, 1). For immunofluorescent staining, phallolidin-AlexaFluor-488 was added to the secondary antibody dilution to visualize F-actin fibers. TO-PRO-3 iodide or 4',6-diamidino-2-phenylindole (DAPI) were used as nuclear counterstains. Images were acquired using an Axiovert S100 epifluorescent/brightfield microscope with a Zeiss N-Achroplan 20 × objective (N.A. = 0.45), a Hamamatsu Orca AG high-end cooled CCD imaging camera, and Meta-morph software operating system (Molecular Devices); or a Zeiss LSM 510 laser scanning confocal microscope with Zeiss Plan-Apochromat 63 × and 40 × oil immersion DIC objectives (N.A. = 1.4), a Hamamatsu CCD imaging camera for widefield imaging on an Axioplan 2 mounting, and Zeiss LSM 510 Meta operating system. Images were equally adjusted for brightness and contrast using Adobe Photoshop CS4 (Version 11.0.2) or Zeiss LSM Image Browser (Version 4.2.0.121).

Antibody array, pull-down assays, and immunoprecipitation

ARY012 antibody arrays (R&D Systems) were incubated with GST or GST-CTLD4 elutes following the manufacturer’s protocol. Relative signal intensities of duplicate spots (mean ± SD) were quantified (Image J version 1.42q) and normalized against the internal positive control. For pull-down assays, GST and GST–fusion proteins conjugated to glutathione–sepharose beads were incubated with cell lysates (4°C, 12 hours), washed in GST-lysis buffer and centrifuged at 14,000 rpm (4°C, 2 minutes; 5×), and denatured (95°C, 5 minutes). Exponentially expressed Endo-Flag chimeric protein (Supplementary Methods) was immunoprecipitated from whole cell lysates using a FLAG-tagged protein immunoprecipitation kit (#FLAGIPT1; Sigma-Aldrich). Pulled down and immunoprecipitated proteins were resolved using SDS-PAGE and immunoblotted (see above).

Statistical analysis

SPSS (Version 19) was used to create Kaplan–Meier plots (censored to account for any patient withdrawals before the final outcome is observed) and to perform log-rank, Breslow, and Tarone–Ware analyses and Student t tests (two-tailed, α = 0.05).

Results

Endo180 expression in early prostate neoplasms decreases survival

Endo180 was analyzed for its contribution to clinical outcome using prostate cancer TMAs that were established at the University...
of Newcastle. In accordance with our earlier findings using a commercial TMA (5), high Endo180 expression was observed in the epithelium, with lesser staining in the stroma, of nonmalignant tumor-adjacent BPH tissue cores (Fig. 1A and Supplementary Table S2); and significant increases in Endo180 expression in PECs in Gleason score 4 and 5 tumor tissue cores compared with nonmalignant tumor-adjacent BPH (Fig. 1B).

The Kaplan–Meier analysis identified Endo180 as an independent predictor of poor prognosis, with only 39% (13/33) deaths recorded after five years for Endo180-negative tumors compared with 65% (60/93) for Endo180-positive tumors [Fig. 1C; Supplementary Table S3, P < 0.02], which despite the relatively low number of patient numbers in this subset indicates that Endo180 expression in these earlier stage neoplasms has a major impact on clinical outcome.

Endo180 is necessary for prostate gland acinar stability

We hypothesized that the significant clinical impact of Endo180 expression at the early stages of prostate cancer results from the negative regulation of its proinvasive function being lost.

To determine if Endo180 contributes to epithelial stability, we genetically silenced the receptor during 3D PEC acinar morphogenesis. In accordance, the loss of Endo180 induced scattering of RWPE-1 and BPH-1 cells into the surrounding rBM (Supplementary Fig. S1A and S1B), without affecting their cell cycle or viability (Supplementary Fig. S2A–S2C), revealing that a critical biologic
function of the receptor in normal glandular PECs is to stabilize their adherence to each other and the basement membrane to help maintain their apical-to-basal polarity.

Endo180 is an uptake receptor for collagen cleavage products generated by the proteolytic activity of membrane type-1 metalloproteinase (MT1-MMP; ref. 15). To test whether silencing of MT1-MMP has a similar effect on acinar architecture to Endo180 knockdown, we depleted MT1-MMP from 3D cultures of RWPE-1 and BPH-1 cells (Supplementary Fig. S1A and S1B). The results confirmed that, unlike Endo180, MT1-MMP is not required for the maintenance of PEC acinar homeostasis. In addition, silencing of Endo180 in 3D aggregates formed by metastatic prostate tumor cells (PTC; PC3 and DU145) did not induce scattering into the surrounding rBM (Supplementary Fig. S1A and S1C), which suggests that Endo180-dependent stabilization of cell–cell adhesions is a molecular mechanism that is exclusive to nontransformed prostatic epithelia.

Endo180 siRNA oligonucleotides #1 and #2 respectively bind to the 3' untranslated region noncoding and mRNA coding regions of the gene (Fig. 2A); therefore, oligonucleotide #1 is not able to silence ectopically expressed Endo180-Flag (Fig. 2B). We used this distinguishing feature of these two oligonucleotides to determine if ectopic expression of Endo180 during endogenous receptor silencing can reverse this dramatic change in acinar architecture. Indeed, ectopic Endo180-Flag expression in PECs rescued the effect of Endo180 siRNA oligonucleotide #1, but not #2, on acinar cell–cell stability (untreated control = 100% fully formed acini; control siRNA = 88.0% ± 18.7%; oligonucleotide #1 = 88.7% ± 24.9%; oligonucleotide #2 = 29.6% ± 5.5%; Fig. 2C and D). As expected, ectopic expression of Flag alone did not rescue the inhibitory effect of either Endo180 siRNA oligonucleotide (untreated control = 100%; control siRNA = 97.7% ± 25.8%; oligonucleotide #1 = 24.1% ± 1.3%; oligonucleotide #2 = 23.2% ± 6.2%; Fig. 2C and D). Acinar morphogenesis by RWPE-1-Flag and RWPE-1-Endo180-Flag cells treated with Endo180 siRNA oligonucleotide #1 was significantly different (Student test: \( P = 0.01 \), two-tailed; Fig. 2D). Moreover, Endo180-Flag was clearly localized to the basolateral membrane of PECs treated with Endo180 siRNA oligonucleotide #1 (Fig. 2C). These data establish that loss of Endo180 from the plasma membrane...
in epithelial cell monolayers may be a driving force behind the switch to an EMT-like phenotype and the dissemination of cells into the surrounding matrix.

CTLD4 in Endo180 receptor modulates glandular epithelial cell–cell adhesion

Differential staining patterns for Endo180 with different mAbs indicated that two subcellular pools of the receptor are present in PEC acini. The first subcellular pool of Endo180 is localized at the basolateral membrane and recognized by A5/158 mAb, whereas the second is localized in endosomes and recognized by 39.10 mAb (Fig. 3A). Treatment with the two antibodies revealed that incubation with 39.10 mAb, but not A5/158, resulted in the same effect as Endo180 silencing by scattering PECs into the surrounding rBM (Fig. 3B). Epitope mapping has confirmed that A5/158 mAb binds to CTLD2 in Endo180 (11). Using a similar epitope mapping approach that involved immunoblot analysis of truncated forms of Endo180 with successive deletions in each of its domains down to CTLD5, it was confirmed that 39.10 mAb binds to CTLD4 (Supplementary Fig. S3A and S3B). This indicates that CTLD4, but not CTLD2, is required for PEC adhesion. The inability of 39.10 mAb to promote cell scattering from 3D aggregates formed by metastatic PTCs (Supplementary Fig. S4) is likely to be the result of constitutive recycling of the receptor from the plasma membrane and its localization to endosomes in transformed mesenchymal-like cells (Fig. 3C; refs. 11, 12).

The strong localization of Endo180 observed at the basolateral membrane of untreated or mouse IgG–treated PEC monolayers was lost following treatment with 39.10 mAb, but not A5/158 mAb, resulting in most of the receptor being localized to endosomes (Fig. 3C). In line with the induction of programmed EMT, the treatment of PECs with 39.10 mAb resulted in a decrease in total cellular levels of E-cadherin (0.3-fold) and β-catenin (0.7-fold; Fig. 3D). In contrast, levels of these core cell–cell adhesion components were unaffected by treatment with A5/158 mAb (E-cadherin: 0.9-fold; β-catenin: 0.9-fold) or IgG control (E-cadherin: 0.8-fold; β-catenin: 1.0-fold; Fig. 3D). Again the disseminated PECs retained their ability to survive, as confirmed by the lack of effect of 39.10 mAb on their cell cycle and viability (Supplementary Fig. S2D–S2G).

We next considered the hypothesis that the inability of 39.10 mAb to recognize Endo180 localized at the plasma membrane is due to CTLD4 epitope being masked by unknown interaction partner(s). We also predicted that treatment with soluble GST-CTLD4 would disrupt epithelial cell–cell contacts by imposing a dominant-negative effect on the unknown interaction partner(s) (Fig. 4A). To test this hypothesis, we generated GST-CTLD2 and GST-CTLD4 chimeric proteins (Fig. 4B) and used them as competing agents for CTLD2 and CTLD4 ligands during PEC acinar morphogenesis. In agreement with antibody-blocking experiments, GST-CTLD4, but not GST-CTLD2, induced scattering of RWPE-1 and BPH-1 cells into the surrounding rBM (Fig. 4C) without affecting cell viability (Supplementary Fig. S2H).

CTLD4 in Endo180 receptor interacts with highly glycosylated CD147

Proteomic analysis of interaction partners eluted from GST-CTLD4–conjugated sepharose beads that had been incubated with PEC whole cell lysates revealed that Endo180 forms a molecular complex with CD147 and CD36 (Fig. 4D and E). Given that CD147 is associated with prostate cancer progression (16), we decided to explore its cooperative role with Endo180.

**Figure 3.**
CTLD4 in Endo180 is required for cell–cell adhesion. A, epitopes in human Endo180 ectodomain recognized by A5/158 and 39.10 mAbs and corresponding immunostaining in RWPE-1 acini (inset); magnification ×63; scale bar, 10 μm. B, RWPE-1 cells cultured in rBM without (untreated) or with mouse IgG, A5/158, and 39.10 for six or 12 days stained with phalloidin (green) and TO-PRO-3 (blue); magnification, ×40; scale bar, 20 μm. C, RWPE-1 and PC3 cell monolayers cultured without (untreated) or with mouse IgG, A5/158, or 39.10 for six days stained with A5/158 (green) and DAPI (blue); magnification, ×63; scale bar, 20 μm. D, immunoblots show E-cadherin, β-catenin, and ERK2 levels in RWPE-1 cells untreated or treated with IgG control or A5/158 and 39.10; MW markers, kDa. Graph shows relative levels of E-cadherin (black bars) and β-catenin (gray bars) adjusted against ERK2 levels and normalized against untreated cells (relative levels = 1).
Endo180–CD147 complex formation was further demonstrated by the ability of GST-CTLD4, but not GST-CTLD2 or GST alone, to bind to the highly glycosylated and active form of CD147 (Supplementary Fig. S5A). Anti-Flag immunoprecipitation of highly glycosylated CD147 from PECs transfected with Endo180-Flag also consolidated its interaction with Endo180 (Supplementary Fig. S5B). Conversely, E-cadherin, β-catenin, and ZO-1 were not detected in Endo180-Flag immunoprecipitates (Supplementary Fig. S5C), suggesting that Endo180 is not incorporated into adherens and tight junction protein complexes. This is not surprising given that Endo180 is weakly localized in lateral cell–cell junctions and strongly localized at the basal plasma membrane of PEC acini (Fig. 3A). In agreement, E-cadherin and β-catenin were not identified as Endo180 interaction partners (Supplementary Fig. S5C).

Endo180–CD147 complex disassembly promotes EMT

Glycosylation of CD147, following its disassociation from caveolin-1, promotes its self-aggregation, stabilization at the plasma membrane and enhanced cell adhesion (17). Based on the ability of highly glycosylated CD147 localized at the plasma membrane to promote cell adhesion, we determined whether its interaction with CTLD4 in Endo180 was responsible for cell–cell adhesion stability in PEC acini. Incubation of PECs with increasing concentrations of the dominant-negative GST-CTLD4 construct decreased the ratio of high/low glycosylated CD147 present in whole cell lysates (2 μg/mL: ratio = 0.71; 4 μg/mL: ratio = 0.25) compared with untreated cells (ratio = 1.0) or cells treated with GST alone (ratio = 1.16) as determined by semiquantitative immunoblot analysis (Fig. 5A). The same treatment did not induce any change in the glycosylation status of CD147 in PTCs (Fig. 5A). Similar to treatment with GST-CTLD4, treatment with 39.10 mAb also decreased the ratio of high/low glycosylated CD147 in PECs (control IgG treatment: ratio = 1.85; 39.10 mAb treatment: ratio = 0.16) but not PTCs (Fig. 5B). The shift in the glycosylation status of CD147—from high to low—induced by GST-CTLD4 in PECs correlated CD147 internalization (Fig. 5C, arrowheads) and unzipping of adherens junctions (Fig. 5C, arrows). These results...
EMT, establishes a new type of molecular trigger for the development of invasive prostate cancer. The findings of this study also confirm that, similar to the upregulation of CD147 (5, 16), the increased expression of Endo180 is correlated with increasing Gleason score (Fig. 1B) and has prognostic value as an independent predictor of overall survival (Fig. 1C). Surprisingly, the Kaplan–Meier analysis revealed that Endo180 is a stronger predictor of survival than Gleason score. However, the cutoff between Gleason 5–7 and Gleason 8–10 used may have skewed the latter outcome given that ≤Gleason 7 (3+4) and ≥Gleason 7 (4+3) scores confer differences in overall survival (18). Future studies using larger patient cohorts are needed to determine if Endo180 expression can differentially affect the survival of men with low (≤Gleason 6) and intermediate [Gleason 7 (3+4)] risk tumors.

Although previous work has suggested that there is a close association between Endo180 expression and an EMT-like phenotype in transformed cells derived from breast (7), pancreatic (10), and prostate (5) cancer, the divergent mechanistic roles of Endo180 in this fundamental process had not been appreciated. Endo180 and CD147 have both been correlated with low levels of E-cadherin in prostate and other glandular epithelia. It will also be important to establish which other specific EMT-associated events, in addition to the downregulation of E-cadherin, are triggered by Endo180–CD147 complex disruption. This analysis could include evaluation of master regulators of EMT, including Snail, Slug, Twist, Zeb, and microRNAs (24).

The characterization of Endo180 for its carbohydrate-binding capacity has so far only included an in vitro analysis that identified CTLD2 as the sole CTLD possessing lectin activity (25). The finding here that CTLD4 in Endo180 binds to highly glycosylated CD147 in 3D acini culture suggests that it also behaves as an active lectin in an in vivo context. Interestingly, in vitro analysis and in vivo evidence have confirmed that lectin activity also resides in the fourth CTLD of the related mannose receptor (26), which points toward an evolutionary basis for the position of this domain in multi-CTLD receptors.

To shed more light on our newly established model of Endo180–CD147-dependent cell–cell adhesion and EMT suppression, we costained PEC acini with anti-CD147 and A5/158 mAbs. The findings revealed that CD147 localizes with Endo180 at the basolateral membrane but not in endosomes (Fig. 6A). Finally, we demonstrated that CD147 silencing (Fig. 6B) also scattered PECs into their surrounding rBM (Fig. 6C), which is in agreement with the pro-EMT effect observed following their treatment with Endo180 siRNA oligonucleotides (Supplementary Fig. S1B) 39.10 mAb (Fig. 3B) and GST-CTLD4 (Fig. 4C).

**Discussion**

The revelation that Endo180 interacts with, and stabilizes, highly glycosylated CD147 at the plasma membrane of normal PECs, and that destabilization of the complex leads to type III
Interestingly, two other cell surface receptors that each have a single CTLD and confined to the tumor vasculature are being considered as molecular targets of antiangiogenics for indirect treatment of solid tumors. The first, CLEC14A (EGFR-5), is exclusively expressed by vascular endothelial cells and promotes cell–cell adhesion and neo-angiogenesis via its single CTLD (27–29). The second, endosialin (CD248, TEM-1), is expressed by stromal fibroblasts and pericytes and can promote tumor angiogenesis and growth (30, 31). Our study now opens the way for CD147 in Endo180 to be characterized for its cooperative role with CD36 (Fig. 4D) and other glycosylated ligands and bona fide lectin activity in addition to its exploitation as a therapeutic target in metastatic cancer.

The importance of CTLD for the formation of the suppressive Endo180–CD147 complex in PECs was not uncovered in Endo180Ex2-6 mice that express a truncated form of the Endo180 receptor, including an intact CTLD4, and reach adulthood (32, 33). Nevertheless, our analysis of prostate tissue from adult Endo180Ex2-6 mice has revealed that a significant architectural change occurs that closely recapitulates prostatic intraepithelial neoplasia, a common precursor for invasive prostate cancer (M. Rodriguez-Teja and colleagues; unpublished data). This finding can be explained by experimental evidence that suggests constitutively exposed CTLD2 in Endo180Ex2-6 mice binds to glycated collagen (34) to promote mechanotransduction and cell invasion (M. Rodriguez-Teja and colleagues; unpublished data). Given that only 3.5% of CD147−/− mice reach adulthood due to failed blastocyst implantation (35), it will be of considerable interest to determine if targeted deletion of CTLD4 or full genetic ablation of Endo180 results in a developmental defect. The impact of Endo180 silencing and Endo180–CTLD4 complex disruption in different glandular epithelia also needs exploration using appropriate in vivo models.

Together with previous findings, this study establishes a new mechanism for the early stages of tumor formation that involves (a) Endo180–CTLD4 and CD147 complex disruption; (b) Endo180 internalization into the cytoplasm via clathrin-dependent endocytosis; (c) CD147 internalization into the cytoplasm via a clathrin-independent mechanism (36); and (d) generation of spatiotemporal contractile signals (RhoA-ROCK-MLC2) from Endo180-containing endosomes that destabilize cell–cell adhesions, increase the turnover of cell–matrix adhesions, and endow disseminated cells with the capacity to migrate via ligand-specific chemotactic mechanisms toward distant sites (refs. 11, 12; Fig. 7). It is also plausible that CD147 and endosomal Endo180 help to coordinate ECM turnover via their respective activation of MMPs (37) and participation in collagen remodeling (7, 8, 14, 34). In addition to inducing Endo180 internalization, Endo180–CTLD4 and CD147 complex disruption deglycosylates and internalizes CD147. Hence, it is possible that Endo180 stabilizes CD147 at the plasma membrane by competing with its negative regulator caveolin-1 (17).

Progression toward metastatic castrate-resistant prostate cancer and the contribution of aberrant androgen signaling to this process remain a major therapeutic challenge (38). Negative androgen receptor (AR) status is correlated with the expression of Endo180 in breast cancer (7). This suggests that dysregulation of the androgen axis and AR signaling may act as a trigger for Endo180 expression and enhanced metastatic potential. A putative role for Endo180 in androgen-independent prostate cancer is further consolidated by its absence from the androgen-dependent and noninvasive LNCaP prostate cancer cell line (8). Together, these observations set a precedent for investigating the interaction between AR signaling and the Endo180 axis.

In combination with the continued validation of soluble Endo180 in serum as a highly sensitive and specific biomarker for metastatic disease (39), the findings of this study suggest that strategies for antimetastatic therapy should (a) promote stabilization of the suppressive complex between CTLD4 in Endo180 and CD147 at the plasma membrane, in the case of indolent diseases like BPH, and (b) exclusively target endosomal Endo180, in the case of aggressive tumors. We predict that the aligned introduction of Endo180 as a prognostic marker and therapeutic target will have a significant impact on the prognosis...
and prevention of metastasis in prostate cancer and could also be of benefit in the management of other types of carcinoma.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: M. Rodriguez-Tejaje, J. Waxman, J. Sturge
Development of methodology: M. Rodriguez-Tejaje, J. Sturge
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): M. Rodriguez-Tejaje, J.H. Gronau, S. Darby, L. Caughan, J. Sturge
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): M. Rodriguez-Tejaje, J.H. Gronau, S. Darby, F. Mauti, J. Sturge
Writing, review, and/or revision of the manuscript: M. Rodriguez-Tejaje, C. Robson, J. Sturge
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): M. Rodriguez-Tejaje, A. Minamidate, J. Waxman, J. Sturge
Study supervision: M. Rodriguez-Tejaje, J. Waxman, J. Sturge

References

Acknowledgments
The authors thank Yoshiki Kawano (Kumamoto University) for technical advice and Isabel Pires (University of Hull) and Catherine Hogan (Cardiff University) for helpful comments during article preparation.

Dedication
This article is dedicated to Peter Gannaway, a good friend, who passed away at age 74 years in December 2012 due to advanced prostate cancer.

Grant Support
This work was supported by grants from The Association of International Cancer Research (grant 08-0803), The Prostate Cancer Charity (grant 110632), The Rosetrees Trust (grants M40/M441), Tony & Rita Gallagher, and Imperial College NHS Healthcare Trust Special Trustees.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received June 18, 2014; revised October 30, 2014; accepted November 1, 2014; published OnlineFirst November 7, 2014.

C-type Lectin Domain Acts as Tumor Suppressor


Survival Outcome and EMT Suppression Mediated by a Lectin Domain Interaction of Endo180 and CD147


Mol Cancer Res  Published OnlineFirst November 7, 2014.

Updated version
Access the most recent version of this article at:
doi:10.1158/1541-7786.MCR-14-0344-T

Supplementary Material
Access the most recent supplemental material at:
http://mcr.aacrjournals.org/content/suppl/2014/11/08/1541-7786.MCR-14-0344-T.DC1

A diagrammatic summary of the major findings and biological implications:
http://mcr.aacrjournals.org/content/early/2015/03/05/1541-7786.MCR-14-0344-T/F1.large.jpg

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://mcr.aacrjournals.org/content/early/2015/03/05/1541-7786.MCR-14-0344-T.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.